An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.

Shafat T, Grupel D, Porges T, Abuhasira R, Belkin A, Deri O, Oster Y, Zahran S, Horwitz E, Horowitz NA, Khatib H, Batista MV, Cortez AC, Brosh-Nissimov T, Segman Y, Ishay L, Cohen R, Atamna A, Spallone A, Chemaly RF, Ramos-Ramos JC, Chowers M, Rogozin E, Oren NC, Keske Ş, Barchad OW, Nesher L, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)

Open source

DOI: 10.1002/cam4.6997
Published: 2024 Feb
Container: Cancer medicine
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.6997,
  title = {An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.},
  author = {Shafat T and Grupel D and Porges T and Abuhasira R and Belkin A and Deri O and Oster Y and Zahran S and Horwitz E and Horowitz NA and Khatib H and Batista MV and Cortez AC and Brosh-Nissimov T and Segman Y and Ishay L and Cohen R and Atamna A and Spallone A and Chemaly RF and Ramos-Ramos JC and Chowers M and Rogozin E and Oren NC and Keske Ş and Barchad OW and Nesher L and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)},
  year = {2024},
  journal = {Cancer medicine},
  doi = {10.1002/cam4.6997},
  url = {https://doi.org/10.1002/cam4.6997}
}

RIS

TY  - JOUR
TI  - An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
AU  - Shafat T
AU  - Grupel D
AU  - Porges T
AU  - Abuhasira R
AU  - Belkin A
AU  - Deri O
AU  - Oster Y
AU  - Zahran S
AU  - Horwitz E
AU  - Horowitz NA
AU  - Khatib H
AU  - Batista MV
AU  - Cortez AC
AU  - Brosh-Nissimov T
AU  - Segman Y
AU  - Ishay L
AU  - Cohen R
AU  - Atamna A
AU  - Spallone A
AU  - Chemaly RF
AU  - Ramos-Ramos JC
AU  - Chowers M
AU  - Rogozin E
AU  - Oren NC
AU  - Keske Ş
AU  - Barchad OW
AU  - Nesher L
AU  - European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)
PY  - 2024
JO  - Cancer medicine
DO  - 10.1002/cam4.6997
UR  - https://doi.org/10.1002/cam4.6997
ER  -

APA

T, S., D, G., T, P., R, A., A, B., O, D., Y, O., S, Z., E, H., NA, H., H, K., MV, B., AC, C., T, B., Y, S., L, I., R, C., A, A., A, S., RF, C., JC, R., M, C., E, R., NC, O., Ş, K., OW, B., L, N., & (ESGREV), E. S. O. C. M. A. I. D. (. S. G. F. R. V. (2024). An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.. Cancer medicine. https://doi.org/10.1002/cam4.6997

Source records

pubmed · retrieved 2026-09-26T18:47:18.875Z
europe-pmc · retrieved 2026-09-26T18:47:18.881Z
doaj · retrieved 2026-09-26T18:47:18.875Z